HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reckitt's New CEO Wants Immediate Changes As OTC Sales Slump In Q3

Executive Summary

RB's new CEO Laxman Narasimhan is unforgiving about how the company has been run over the past few years and believes things need to change after another disappointing quarter. 

You may also be interested in...



RB To Split OTC And Infant Nutrition As CEO Hits Reset Button

Reckitt Benckiser's new CEO Laxman Narasimhan has unveiled a turnaround plan which will see the company's OTC drugs and dietary supplements housed in a separate business to its infant nutrition products. RB is investing £2bn to get back on track after a couple of difficult years.

Reckitt Names New CEO To Ignite Growth And Lead Digital Transformation

Reckitt Benckiser has poached PepsiCo's global chief commercial officer, Laxman Narasimhan, to replace Rakesh Kapoor as the UK-based firm's CEO. Setting his stall out early, Narasimhan has made clear that RB's "capabilities and culture" need to change to make the company fit for the new digital world.

Infant Formula Production Stalls On Reckitt Benckiser's Latest Stumble

A "technical problem" interrupted infant formula production at firm's Netherlands plant during third quarter, causing a 8% dive in its revenues from Enfamil and other brand formulas. The problem has been corrected but revenues will be slowed during the current quarter and likely into early 2019.  But analysts say the imapct could be deeper impact because it's the fourth problems since 2011 RB should have avoided.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel